Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

BACKGROUND: The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell–receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Byrd, John C., Furman, Richard R., Coutre, Steven E., Flinn, Ian W., Burger, Jan A., Blum, Kristie A., Grant, Barbara, Sharman, Jeff P., Coleman, Morton, Wierda, William G., Jones, Jeffrey A., Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Sukbuntherng, Juthamas, Chang, Betty Y., Clow, Fong, Hedrick, Eric, Buggy, Joseph J., James, Danelle F., O'Brien, Susan
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3772525/
https://ncbi.nlm.nih.gov/pubmed/23782158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1215637
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items